Completing data — usually done within a minute
Basic information
- CAS
137234-62-9- Standard SMILES
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F- InChIKey
BCEHBSKCWLPMDN-MGPLVRAMSA-N- Molecular formula
- C16H14F3N5O
- Average molar mass
- 349.316 g/mol
- Monoisotopic mass
- 349.11504473
Names & identifiers
- Preferred name
- (+/-)-Voriconazole
- IUPAC
- (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
- English name
- Voriconazole-d3
- Molecular formula
- C16H14F3N5O
- Molecular weight
- 349.31
Names & synonyms
Database identifiers
- CAS
137234-62-9、188416-29-7- PubChem CID
- 71616
- DTXSID
DTXSID201019420- ChEMBL
CHEMBL638- ChEBI
CHEBI:10023- UNII
- JFU09I87TR、USG4B1CD29
- EC Number
- 629-701-5、941-833-8
- Nikkaji
- J709.476K
Properties
Physicochemical properties
- Boiling point
- 508.6 · 508.6±60.0 °C(Predicted)
- Density
- 1.42 · 1.42±0.1 g/cm3(Predicted)
- storage temp.
- 2 · Storage temp. 2-8°C
- pka
- 11.54 · 11.54±0.29(Predicted)
- form
- Solid
- color
- White to off-white
- InChI
- InChI=1/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/s3
- InChIKey
- BCEHBSKCWLPMDN-NLBNCHMPNA-N
- SMILES
- C[C@@H]([C@@](CN1C=NC=N1)(C1C(F)=CC(F)=CC=1)O)C1C(F)=CN=CN=1 |&1:1,2,r|
- FDA UNII
- 4 B1CD29 · USG4B1CD29
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302-H315-H319-H335
- Precautionary statements
- 261 · P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501
Safety & regulation
Safety data
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- Hazard statements
- H302-H315-H319-H335
- Precautionary statements
- P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501
Chemistry & industry
Applications
DescriptionVoriconazole-d3 is an Ergosterol biosynthesis inhibitor and a labeled form of Voriconazole. This mono triazole antifungal agent inhibits the growth of Candida, Cryptococcus, and Aspergillus species. Studies suggest that Voriconazole-d3 can be synthesized by modifying the structure of fluconazole. This antifungal agent functions by inhibiting cytochrome P450 dependent 14-α-sterol demethylase, which is responsible for the biosynthesis of Ergosterol. Furthermore, Voriconazole-d3 inhibits fungal growth, cell wall thinning, and cell membrane degradation.
UsesVoriconazole is a triazole antifungal agent used primarily in the treatment or prevention of aspergillosis and candidal infections. However, its therapy may cause transient, asymptomatic serum aminotransferase elevations, and it is also a well-known cause of acute drug-induced liver injury.
Suppliers67 total
Related reactions
Compound notes
Loading…